Keywords
Last Name
Institution

MARIA E CABANILLAS

TitleAssociate Professor
InstitutionMD Anderson
DepartmentEndocrine Neoplasia & HD
Address1400 Pressler St
Houston TX 77030-4008
vCardDownload vCard

    Collapse Additional Tools and Researcher Information 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Iyer PC, Dadu R, Ferrarotto R, Busaidy NL, Habra MA, Zafereo M, Gross N, Hess KR, Gule-Monroe M, Williams MD, Cabanillas ME. Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma. Thyroid. 2018 Jan; 28(1):79-87. PMID: 29161986.
      View in: PubMed
    2. Rao SN, Zafereo M, Dadu R, Busaidy N, Hess K, Cote GJ, Williams MD, William WN, Sandulache VC, Gross ND, Gunn B, Lu C, Ferrarotto R, Lai SY, Cabanillas M. Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma. Thyroid. 2017 Jan 09. PMID: 28068873.
      View in: PubMed
    3. Pezzi TA, Mohamed AS, Sheu T, Blanchard P, Sandulache VC, Lai SY, Cabanillas ME, Williams MD, Pezzi CM, Lu C, Garden AS, Morrison WH, Rosenthal DI, Fuller CD, Gunn GB. Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data Base. Cancer. 2016 Dec 27. PMID: 28026871.
      View in: PubMed
    4. Sandulache VC, Williams MD, Lai SY, Lu C, William WN, Busaidy NL, Cote GJ, Singh RR, Luthra R, Cabanillas ME. Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma. Thyroid. 2017 Jan; 27(1):81-87. PMID: 27785980.
      View in: PubMed
    5. Pezzi TA, Sandulache VC, Pezzi CM, Turkeltaub AE, Feng L, Cabanillas ME, Williams MD, Lai SY. Treatment and survival of patients with insular thyroid carcinoma: 508 cases from the National Cancer Data Base. Head Neck. 2016 Jun; 38(6):906-12. PMID: 26843481.
      View in: PubMed
    6. Cabanillas ME, Habra MA. Lenvatinib: Role in thyroid cancer and other solid tumors. Cancer Treat Rev. 2016 Jan; 42:47-55. PMID: 26678514.
      View in: PubMed
    7. Cabanillas ME, Dadu R, Hu MI, Lu C, Gunn GB, Grubbs EG, Lai SY, Williams MD. Thyroid Gland Malignancies. Hematol Oncol Clin North Am. 2015 Dec; 29(6):1123-43. PMID: 26568552.
      View in: PubMed
    8. Schlumberger M, Jarzab B, Cabanillas ME, Robinson B, Pacini F, Ball DW, McCaffrey J, Newbold K, Allison R, Martins RG, Licitra LF, Shah MH, Bodenner D, Elisei R, Burmeister L, Funahashi Y, Ren M, O'Brien JP, Sherman SI. A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer. Clin Cancer Res. 2016 Jan 1; 22(1):44-53. PMID: 26311725.
      View in: PubMed
    9. Dadu R, Hu MI, Cleeland C, Busaidy NL, Habra M, Waguespack SG, Sherman SI, Ying A, Fox P, Cabanillas ME. Efficacy of the Natural Clay, Calcium Aluminosilicate Anti-Diarrheal, in Reducing Medullary Thyroid Cancer-Related Diarrhea and Its Effects on Quality of Life: A Pilot Study. Thyroid. 2015 Oct; 25(10):1085-90. PMID: 26200040.
      View in: PubMed
    10. Weitzman SP, Cabanillas ME. The treatment landscape in thyroid cancer: a focus on cabozantinib. Cancer Manag Res. 2015; 7:265-78. PMID: 26316818.
      View in: PubMed
    11. Ozsari L, Kutahyalioglu M, Elsayes KM, Vicens RA, Sircar K, Jazaerly T, Waguespack SG, Busaidy NL, Cabanillas ME, Dadu R, Hu MI, Vassilopoulou-Sellin R, Jimenez C, Lee JE, Habra MA. Preexisting adrenal masses in patients with adrenocortical carcinoma: clinical and radiological factors contributing to delayed diagnosis. Endocrine. 2016 Feb; 51(2):351-9. PMID: 26206754.
      View in: PubMed
    12. Cabanillas ME, Schlumberger M, Jarzab B, Martins RG, Pacini F, Robinson B, McCaffrey JC, Shah MH, Bodenner DL, Topliss D, Andresen C, O'Brien JP, Ren M, Funahashi Y, Allison R, Elisei R, Newbold K, Licitra LF, Sherman SI, Ball DW. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. Cancer. 2015 Aug 15; 121(16):2749-56. PMID: 25913680.
      View in: PubMed
    13. Dadu R, Shah K, Busaidy NL, Waguespack SG, Habra MA, Ying AK, Hu MI, Bassett R, Jimenez C, Sherman SI, Cabanillas ME. Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience. J Clin Endocrinol Metab. 2015 Jan; 100(1):E77-81. PMID: 25353071; PMCID: PMC4283003.
    14. Falchook GS, Millward M, Hong D, Naing A, Piha-Paul S, Waguespack SG, Cabanillas ME, Sherman SI, Ma B, Curtis M, Goodman V, Kurzrock R. BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. Thyroid. 2015 Jan; 25(1):71-7. PMID: 25285888; PMCID: PMC4291160.
    15. Cabanillas ME, Patel A, Danysh BP, Dadu R, Kopetz S, Falchook G. BRAF inhibitors: experience in thyroid cancer and general review of toxicity. Horm Cancer. 2015 Feb; 6(1):21-36. PMID: 25467940.
      View in: PubMed
    16. Cabanillas ME, Hu MI, Jimenez C. Medullary thyroid cancer in the era of tyrosine kinase inhibitors: to treat or not to treat--and with which drug--those are the questions. J Clin Endocrinol Metab. 2014 Dec; 99(12):4390-6. PMID: 25238206.
      View in: PubMed
    17. Cabanillas ME, Brose MS, Holland J, Ferguson KC, Sherman SI. A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer. Thyroid. 2014 Oct; 24(10):1508-14. PMID: 25102375; PMCID: PMC4195402.
    18. Cabanillas ME, Dadu R, Lai SY. In reply. Oncologist. 2014 Aug; 19(8):e4. PMID: 25052450.
      View in: PubMed
    19. Baudin E, Habra MA, Deschamps F, Cote G, Dumont F, Cabanillas M, Arfi-Roufe J, Berdelou A, Moon B, Al Ghuzlan A, Patel S, Leboulleux S, Jimenez C. Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma. Eur J Endocrinol. 2014 Sep; 171(3):R111-22. PMID: 24891137.
      View in: PubMed
    20. Holsinger FC, Ramaswamy U, Cabanillas ME, Lang J, Lin HY, Busaidy NL, Grubbs E, Rahim S, Sturgis EM, Lee JE, Weber RS, Clayman GL, Rohren EM. Measuring the extent of total thyroidectomy for differentiated thyroid carcinoma using radioactive iodine imaging: relationship with serum thyroglobulin and clinical outcomes. JAMA Otolaryngol Head Neck Surg. 2014 May; 140(5):410-5. PMID: 24700275.
      View in: PubMed
    21. Dadu R, Waguespack SG, Sherman SI, Hu MI, Busaidy NL, Jimenez C, Habra MA, Ying AK, Bassett RL, Cabanillas ME. Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer. Oncologist. 2014 May; 19(5):477-82. PMID: 24733667; PMCID: PMC4012968.
    22. Blevins DP, Dadu R, Hu M, Baik C, Balachandran D, Ross W, Gunn B, Cabanillas ME. Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer. Thyroid. 2014 May; 24(5):918-22. PMID: 24635127; PMCID: PMC4026371.
    23. Dadu R, Devine C, Hernandez M, Waguespack SG, Busaidy NL, Hu MI, Jimenez C, Habra MA, Sellin RV, Ying AK, Cote GJ, Sherman SI, Cabanillas ME. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab. 2014 Jun; 99(6):2086-94. PMID: 24628550; PMCID: PMC4037722.
    24. Thomas L, Lai SY, Dong W, Feng L, Dadu R, Regone RM, Cabanillas ME. Sorafenib in metastatic thyroid cancer: a systematic review. Oncologist. 2014 Mar; 19(3):251-8. PMID: 24563075; PMCID: PMC3958462.
    25. Ganeshan D, Paulson E, Duran C, Cabanillas ME, Busaidy NL, Charnsangavej C. Current update on medullary thyroid carcinoma. AJR Am J Roentgenol. 2013 Dec; 201(6):W867-76. PMID: 24261394.
      View in: PubMed
    26. Kim KB, Cabanillas ME, Lazar AJ, Williams MD, Sanders DL, Ilagan JL, Nolop K, Lee RJ, Sherman SI. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Thyroid. 2013 Oct; 23(10):1277-83. PMID: 23489023; PMCID: PMC3967415.
    27. Hightower E, Cabanillas ME, Fuller GN, McCutcheon IE, Hess KR, Shah K, Waguespack SG, Corley LJ, Devin JK. Phospho-histone H3 (pHH3) immuno-reactivity as a prognostic marker in non-functioning pituitary adenomas. Pituitary. 2012 Dec; 15(4):556-61. PMID: 22120760; PMCID: PMC3852837.
    28. Dadu R, Cabanillas ME. Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions. Minerva Endocrinol. 2012 Dec; 37(4):335-56. PMID: 23235190; PMCID: PMC3980664.
    29. Carhill AA, Cabanillas ME, Jimenez C, Waguespack SG, Habra MA, Hu M, Ying A, Vassilopoulou-Sellin R, Gagel RF, Sherman SI, Busaidy NL. The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab. 2013 Jan; 98(1):31-42. PMID: 23185034; PMCID: PMC3537108.
    30. Ayala-Ramirez M, Chougnet CN, Habra MA, Palmer JL, Leboulleux S, Cabanillas ME, Caramella C, Anderson P, Al Ghuzlan A, Waguespack SG, Deandreis D, Baudin E, Jimenez C. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J Clin Endocrinol Metab. 2012 Nov; 97(11):4040-50. PMID: 22965939; PMCID: PMC3683800.
    31. Del Fabbro E, Dev R, Cabanillas ME, Busaidy NL, Rodriguez EC, Bruera E. Extreme hypothyroidism associated with sunitinib treatment for metastatic renal cancer. J Chemother. 2012 Aug; 24(4):221-5. PMID: 23040687; PMCID: PMC4058856.
    32. Vu K, Busaidy N, Cabanillas ME, Konopleva M, Faderl S, Thomas DA, O'Brien S, Broglio K, Ensor J, Escalante C, Andreeff M, Kantarjian H, Lavis V, Yeung SC. A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2012 Oct; 12(5):355-62. PMID: 22658895; PMCID: PMC3974971.
    33. Cabanillas ME, Sherman SI. Applying new clinicopathological characteristics to prognostication in advanced thyroid carcinoma. Endocr Relat Cancer. 2012 Apr; 19(2):C19-22. PMID: 22241721; PMCID: PMC4039023.
    34. Busaidy NL, Cabanillas ME. Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease. J Thyroid Res. 2012; 2012:618985. PMID: 22530159; PMCID: PMC3316972.
    35. M Bugalho MJ, Wohllk N, Hoff AO, Cabanillas ME. Thyroid oncology. J Thyroid Res. 2011; 2011:467570. PMID: 22007337.
      View in: PubMed
    36. Cabanillas ME, Hu MI, Durand JB, Busaidy NL. Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer. J Thyroid Res. 2011; 2011:985780. PMID: 22007339; PMCID: PMC3189619.
    37. Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, Xiao L, Bekele BN, Foudray MC, Cortes JE. Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial. Cancer. 2012 Feb 1; 118(3):848-55. PMID: 21751205.
      View in: PubMed
    38. Ejaz S, Vassilopoulou-Sellin R, Busaidy NL, Hu MI, Waguespack SG, Jimenez C, Ying AK, Cabanillas M, Abbara M, Habra MA. Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion: the University of Texas MD Anderson Cancer Center Experience. Cancer. 2011 Oct 1; 117(19):4381-9. PMID: 21412758; PMCID: PMC3134535.
    39. Hong DS, Cabanillas ME, Wheler J, Naing A, Tsimberidou AM, Ye L, Busaidy NL, Waguespack SG, Hernandez M, El Naggar AK, El Naggar AK, Bidyasar S, Wright J, Sherman SI, Kurzrock R. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J Clin Endocrinol Metab. 2011 Apr; 96(4):997-1005. PMID: 21289252; PMCID: PMC3070247.
    40. Mattiuzzi GN, Cortes JE, Blamble DA, Bekele BN, Xiao L, Cabanillas M, Borthakur G, O'Brien S, Kantarjian H. Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia. Cancer. 2010 Dec 15; 116(24):5659-66. PMID: 21218459.
      View in: PubMed
    41. Garcia-Doval I, Cabo F, Monteagudo B, Alvarez J, Ginarte M, Rodríguez-Alvarez MX, Abalde MT, Fernández ML, Allegue F, Pérez-Pérez L, Flórez A, Cabanillas M, Peón G, Zulaica A, Del Pozo J, Gomez-Centeno P. Clinical diagnosis of toenail onychomycosis is possible in some patients: cross-sectional diagnostic study and development of a diagnostic rule. Br J Dermatol. 2010 Oct; 163(4):743-51. PMID: 20618320.
      View in: PubMed
    42. Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, Lopez A, Sherman SI, Busaidy NL. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin Endocrinol Metab. 2010 Jun; 95(6):2588-95. PMID: 20392874.
      View in: PubMed
    43. Hernández A, Domper F, León A, Lorente R, López B, de la Santa E, Cabanillas M, Patón R, Olmedo J, Galván MD, Rodríguez E. Viral kinetics during the first month of treatment in patients with genotype 1 chronic hepatitis C. Rev Esp Enferm Dig. 2009 Oct; 101(10):671-9. PMID: 19899935.
      View in: PubMed
    44. Monteagudo Sánchez B, Cabanillas M, Caínzos T, Used-Aznar MM. [Merkel cell carcinoma of the breast]. Actas Dermosifiliogr. 2009 Mar; 100(2):151-2. PMID: 19445883.
      View in: PubMed
    45. Ginarte M, Garcia-Doval I, Monteagudo B, Cabanillas M, Labandeira J, Florez A, Cabo F, Alvarez J, Zulaica A, Allegue F, Pérez L, Abalde MT, Rosón E, de la Torre C, Rodríguez MX. Observer agreement in toenail disorders: implications for diagnosis and clinical research. Br J Dermatol. 2009 Jun; 160(6):1315-7. PMID: 19239464.
      View in: PubMed
    46. Jimenez C, Cabanillas ME, Santarpia L, Jonasch E, Kyle KL, Lano EA, Matin SF, Nunez RF, Perrier ND, Phan A, Rich TA, Shah B, Williams MD, Waguespack SG. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J Clin Endocrinol Metab. 2009 Feb; 94(2):386-91. PMID: 19017755.
      View in: PubMed
    47. León-Muiños E, Monteagudo B, Labandeira J, Cabanillas M. [Bilateral congenital triangular alopecia associated with congenital heart disease and renal and genital abnormalities]. Actas Dermosifiliogr. 2008 Sep; 99(7):578-9. PMID: 18682178.
      View in: PubMed
    48. Cabanillas M, Rodríguez-Blanco I, Sánchez-Aguilar D, Toribio J. [Sweet syndrome as a possible initial manifestation of human immunodeficiency virus infection]. Actas Dermosifiliogr. 2008 Jan-Feb; 99(1):83-4. PMID: 18206098.
      View in: PubMed
    49. Cabanillas ME, Lu H, Fang S, Du XL. Elderly patients with non-Hodgkin lymphoma who receive chemotherapy are at higher risk for osteoporosis and fractures. Leuk Lymphoma. 2007 Aug; 48(8):1514-21. PMID: 17701582.
      View in: PubMed
    50. Torres HA, Aguilera EA, Mattiuzzi GN, Cabanillas ME, Rohatgi N, Sepulveda CA, Kantarjian HM, Jiang Y, Safdar A, Raad II, Chemaly RF. Characteristics and outcome of respiratory syncytial virus infection in patients with leukemia. Haematologica. 2007 Sep; 92(9):1216-23. PMID: 17666367.
      View in: PubMed
    51. Berrios-Rivera JP, Fang S, Cabanillas ME, Cabanillas F, Lu H, Du XL. Variations in chemotherapy and radiation therapy in a large nationwide and community-based cohort of elderly patients with non-Hodgkin lymphoma. Am J Clin Oncol. 2007 Apr; 30(2):163-71. PMID: 17414466.
      View in: PubMed
    52. Chemaly RF, Torres HA, Aguilera EA, Mattiuzzi G, Cabanillas M, Kantarjian H, Gonzalez V, Safdar A, Raad II. Neuraminidase inhibitors improve outcome of patients with leukemia and influenza: an observational study. Clin Infect Dis. 2007 Apr 1; 44(7):964-7. PMID: 17342649.
      View in: PubMed
    53. Jabbour E, O'Brien S, Kantarjian H, Garcia-Manero G, Ferrajoli A, Ravandi F, Cabanillas M, Thomas DA. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood. 2007 Apr 15; 109(8):3214-8. PMID: 17209054.
      View in: PubMed
    54. Weiser MA, Cabanillas M, Vu K, Tamm EP, Wallace MJ, Escalante CP, Bresalier RS. Diagnostic evaluation of patients with a high suspicion of malignancy: comorbidities and clinical predictors of cancer. Am J Med Sci. 2005 Jul; 330(1):11-8. PMID: 16020994.
      View in: PubMed
    55. Weiser MA, Cabanillas ME, Konopleva M, Thomas DA, Pierce SA, Escalante CP, Kantarjian HM, O'Brien SM. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Cancer. 2004 Mar 15; 100(6):1179-85. PMID: 15022284.
      View in: PubMed
    56. Spine Stereotactic Radiosurgery for Patients with Metastatic Thyroid Cancer. Thyroid. 26:1269-1275.
    57. Treatment and survival of patients with insular thyroid carcinoma. Head and Neck.
    58. Anaplastic thyroid carcinoma. Journal of Oncology Practice. 12:511-518.
    59. Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma. Cancer.
    60. A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer. Clinical Cancer Research. 22:44-53.
    61. Targets by organ site.
    62. Role of CDKN2C copy number in sporadic medullary thyroid carcinoma. Thyroid. 26:1553-1562.
    63. Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma. Thyroid. 27:81-87.
    64. Re. Oncologist. 19.
    65. Bone metastases and skeletal-related events in medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism. 101:4871-4877.
    66. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies (Journal of Clinical Endocrinology and Metabolism (2011) 96, 997-1005). Journal of Clinical Endocrinology and Metabolism. 96:2286.
    67. Efficacy of the natural clay, calcium aluminosilicate anti-diarrheal, in reducing medullary thyroid cancer-related diarrhea and its effects on quality of life. Thyroid. 25:1085-1090.
    68. Efficacy and tolerability of vemurafenib in patients with BRAFV600E positive papillary thyroid cancer. Journal of Clinical Endocrinology and Metabolism. 100:E77-E81.
    69. The treatment landscape in thyroid cancer. Cancer Management and Research. 7:265-278.
    70. Thyroid cancer. The Lancet.
    71. Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine. The Lancet Oncology. 17:1272-1282.
    72. Detection and prognostic significance of circulating tumor cells in patients with metastatic thyroid cancer. Journal of Clinical Endocrinology and Metabolism. 101:4461-4467.
    73. Preexisting adrenal masses in patients with adrenocortical carcinoma. Endocrine.
    74. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies (Journal of Clinical Endocrinology and Metabolism (2011) 96, (997-1005)). Journal of Clinical Endocrinology and Metabolism. 97:1399.
    75. Long-Term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model. Oncotarget. 7:30907-30923.
    CABANILLAS's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description